Rare mutations, such as the HER2 mutation and MET exon 14 skipping, can co‐occur with EGFR mutations, and patients with these types of coalteration have been reported to respond well to EGFR‐TKI or combined therapy.12, 24 In our center, patients first diagnosed with NSCLC were routinely screened for EGFR, ALK, ROS1, KRAS, and BRAF alterations. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.